KEISUKE GOTO

Last Updated :2025/04/03

Web Site
https://home.hiroshima-u.ac.jp/urology/index_English.html
E-mail
keigotohiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2004/05, 2006/03, Hiroshima University, Hospital, Clinical Resident
  • 2006/04, 2006/06, Hiroshima University, Hospital, Clinical Fellow
  • 2006/07, 2008/06, JA Hiroshima General Hospital, Doctor
  • 2008/07, 2010/03, Takanobashi Central Hospital, Doctor
  • 2016/04/01, 2016/11/30, Hiroshima University, Hospital, Clinical Fellow
  • 2016/12, 2018/12, University of Hawaii Cancer Center, Postdoctoral Research Fellow
  • 2019/01/01, Hiroshima University, Hospital, Assistant Professor

Academic Degrees

  • Hiroshima University

Affiliated Academic Societies

Educational Activity

Course in Charge

  1. 2025, Undergraduate Education, Year, Clinical diagnosis and treatment II
  2. 2025, Undergraduate Education, Intensive, Symptomatology, Diagnosis and Treatment
  3. 2025, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2025, Graduate Education (Doctoral Program) , 1Term, Practice of Oncology

Research Activities

Academic Papers

  1. ★, A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations., Journal of Clinical Oncology, 36(35), 3485-3494
  2. Fibroblast Growth Factor Family in the Progression of Prostate Cancer, JOURNAL OF CLINICAL MEDICINE, 8(2), 201902
    Link to Paper Search Results by DOI
  3. Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients., The Prostate, 79(2), 2019
  4. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer., International journal of molecular sciences, 20(16), 2019
  5. Tubulocystic renal cell carcinoma: a review of literature focused on radiological findings for differential diagnosis., Abdominal radiology (New York), 43(7), 2018
  6. Uc.416 + A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma., BMC cancer, 18(1), 2018
  7. Imaging features of papillary renal cell carcinoma with cystic change-dominant appearance in the era of the 2016 WHO classification., Abdominal radiology (New York), 42(7), 2017
  8. Transcribed ultraconserved region Uc.63+ promotes resistance to docetaxel through regulation of androgen receptor signaling in prostate cancer., Oncotarget, 8(55), 2017
  9. The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation., Oncogene, 35(27), 2016
  10. A case of tubulocystic carcinoma of the kidney with aggressive features., Japanese journal of radiology, 34(4), 2016
  11. Serous adenocarcinoma of retroperitoneum: a case report., International cancer conference journal, 6(4), 2017
  12. Clinical staging of upper urinary tract urothelial carcinoma for T staging: Review and pictorial essay, INTERNATIONAL JOURNAL OF UROLOGY, 2019
  13. Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer, INTERNATIONAL JOURNAL OF UROLOGY, 24(8), 594-600, 2017
  14. Subtype classification by urothelial differentiation markers stratified prognosis in patients with muscle invasive bladder cancer, INTERNATIONAL JOURNAL OF UROLOGY, 25, 235-235, 2018
  15. Inguinal hernia after radical perineal prostatectomy: Comparison with the retropubic approach, UROLOGY, 70(6), 1152-1156, 2007
  16. MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma, INTERNATIONAL JOURNAL OF UROLOGY, 20(5), 468-477, 2013
  17. Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 32(6), 769-778, 2014
  18. FGF19 Promotes Progression of Prostate Cancer, PROSTATE, 75(10), 1092-1101, 2015
  19. Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection., Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 8(5-6), 2014
  20. Expression of miR-486 is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma., Molecular and clinical oncology, 1(2), 2013
  21. Accumulation of FGF9 in prostate cancer correlates with epithelial-to-mesenchymal transition and induction of VEGF-A expression., Anticancer research, 34(2), 2014
  22. Comparison of initial experiences of robot-assisted radical cystectomy with those of laparoscopic for bladder cancer., Innovations (Philadelphia, Pa.), 9(4), 2014
  23. ACUTE RENAL FAILURE FOLLOWING ADMINISTRATION OF eVEROLIMUS FOR METASTA TIC RENAL CELL CARCINOMA : A CASE REPORT, 75(7), 383-389, 20130720
  24. Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels., Molecular and clinical oncology, 6(5), 2017
  25. Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma., Cancer medicine, 6(10), 2017
  26. Preoperative risk classification using neutrophil-lymphocyte ratio and hydronephrosis for upper tract urothelial carcinoma., Japanese journal of clinical oncology, 48(9), 2018
  27. Anastomosing haemangioma with fatty changes in the perirenal space: a lesion mimicking liposarcoma., BJR case reports, 4(2), 2018

Invited Lecture, Oral Presentation, Poster Presentation

  1. Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation, Tetsutaro Hayashi, Kazuhiro Sentani, Hiroshima, Japan; Kenichiro Ikeda, Vancouver, Canada; Keisuke Goto, Hawaii, HI; Htoo Zarni Oo, Vancouver, Canada; Hamidreza Abdi, Ottawa, Canada,Shunsuke Shinmei, Shogo Inoue, Jun Teishima, Wataru Yasui,Hiroshima, Japan; Peter C Black, Vancouver, Canada; Akio Matsubara, AUA2019, 2019/05/03, Without Invitation, English, Chicago
  2. Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation., Tetsutaro Hayashi, Kazuhiro Sentani, Kenichiro Ikeda, Keisuke Goto, Htoo Zarni Oo, Hamidreza Abdi Shunsuke Shinmei, Shogo Inoue, Jun Teishima, Wataru Yasui, Peter C Black and Akio Matsubara., 34th Annual EAU Congress, 2019/03/15, Without Invitation, English, Barcelona
  3. Accurate clinical T3 staging by a Computed Tomography scoring system is an independent preoperative predictor of survival in patients with urothelial carcinoma of the ureter., Tetsutaro Hayashi, Keisuke Goto, Yukiko Honda, Ryan S Hsi, Kazuhiro Sentani, Ikeda Kenichiro, Yuki Kohada, Shunsuke Shinmei, Shogo Inoue, Jun Teishima, Wataru Yasui, Kazuo Awai and Akio Matsubara., 34th Annual EAU Congress, 2019/03/15, Without Invitation, English, Barcelona
  4. PCDHB9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients., Sekino Y. , Goto K , Sakamoto N , Oue N , Sentani K , Hayashi T, Teishima J , Yasui A , Matsubara A, 34th Annual EAU Congress, 2019/03/15, Without Invitation, English, Barcelona
  5. FGF family in progression of prostate cancer., Jun Teishima,Tetsutaro Hayashi,Hirotaka Nagamatsu,Koichi Shoji,Keisuke Goto, Akio Matsubara, 第5回前立線生物学シンポジウム伊勢志摩2018, 2018/07/12, Without Invitation, English, Toba
  6. Immunohistochemical classification using urothelial differentiation markers can stratify prognosis in patients with muscle invasive bladder cancer, Tetsutaro Hayashi, Kazuhiro Sentani, Keisuke Goto, Htoo Zarni Oo,Hamidreza Abdi, Kazuaki Mutaguchi, Nakatsu, Japan, Shunsuke Shinmei, Shogo Inoue, Jun Teishima, Wataru Yasui, Peter C Black,, Akio Matsubara, 2018 AUA Annual Meeting, 2018/05/17, Without Invitation, English
  7. Uc.63+ promotes resistance to docetaxel through androgen receptor signaling and a promising serum biomarker for docetaxel treatment in prostate cancer, Yohei Sekino,Naoya Sakamoto, Keisuke Goto, Ririno Honma, Yoshinori Shigematsu, Kazuhiro Sentani, Naohide Oue, Jun Teishima, Wataru Yasui, Akio Matsubara, 第106回日本泌尿器科学会総会, 2018/04/19, Without Invitation, Japanese
  8. Subtype classification by urothelial differentiation markers stratified prognosis in patients with muscle invasive bladder cancer, Tetsutaro Hayashi,Kazuhiro Sentani, Keisuke Goto, Kazuaki Mutaguchi, Kohei Kobatake, Shunsuke Shinmei, Shogo Inoue, Jun Teishima, Wataru Yasui, Akio Matsubara, 16th UAA Congress 2018, 2018/04/18, Without Invitation, English, Kyoto
  9. Transcribed ultraconserved region Uc.63+ promotes resistance to docetaxel through regulation of androgen receptor signaling in prostate cancer, SekinoY.SakamotoN.GotoK.HonmaR.ShigematsuY.SentaniK.OueN.TeishimaJ.YasuiW.MatsubaraA., EAU European Association Urology 2018, 2018/03/16, Without Invitation, English, Copenhagen
  10. Significance of endocrine fibroblast growth factor subfamily as serum biomarkers in castration-resistant prostate cancer, Jun Teishima, Yuka Yamaguchi, Hirotaka Nagamatsu, Hiroyuki Shikuma, Shinsuke Fujii, Keisuke Goto, Shunsuke Shinmei, Shogo Inoue, Tetsutaro Hayashi, Akio Matsubara, 2010/09/27, Without Invitation, Japanese